Sino Biological Sets New Industry Standard with ProPure™ Endotoxin-Free Proteins

This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.

The newly released proteins are manufactured using advanced purification and production technologies, ensuring endotoxin levels below the limit of quantification (LOQ). By leveraging mammalian expression systems and proprietary purification protocols, the C4B delivers high-purity proteins tailored for sensitive applications where even trace endotoxin contamination can compromise results or patient safety.

“Our commitment to scientific excellence and product safety has driven us to develop this next generation of endotoxin-free proteins” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. “Researchers and biomanufacturers can now rely on the C4B for products that support the highest standards of quality and consistency, empowering breakthroughs in both basic and translational science.”

The launch of ProPure™ product line underscores Sino Biological’s ongoing investment in bioprocessing innovation and its dedication to supporting the global life sciences community. In addition to standard offerings, the C4B provides customized protein development services, and made-to-order new product development to address unique research and production needs.

About Sino Biological

Sino Biological is an international reagent supplier and contract research service provider. The company specializes in recombinant protein production and antibody development. Most of Sino Biological’s products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research.  In addition, Sino Biological offers contract research production services for the custom development of full length, bioactive proteins and high-affinity antibodies, along with other services. To learn more about Sino Biological visit www.sinobiological.com, follow the company on LinkedIn or @SinoInc on Twitter.

Forward-Looking Statements

Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For more information about C4B’s endotoxin-free protein products or to discuss custom solutions, please contact:

Email: cro_us@sinobiologicalus.com
Phone: 215-583-7898

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com